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The search for inherited cancer susceptibility factors is a major focus of epidemiologic cancer studies. Analyses of single-nucleotide
polymorphisms (SNP) in a variety of genes revealed a correlation between a specific allele variant and cancer predisposition. Human
mouse double-minute 2 protein (Mdm2) is a cellular E3 ligase capable of ubiquitination and degradation of p53. Therefore, Mdm2 is a
crucial factor of cell cycle control and cell survival. The Mdm2 promoter SNP309 was shown to increase Mdm2 expression and can,
thereby, inhibit the p53 pathway. This SNP was found to be associated with increased risk and early onset of various malignancies. For
prostate cancer no studies are reported to date. In a case–control study we determined the distribution of the Mdm2 SNP309 in
145 male subjects with prostate cancer and in 124 male controls without any malignancy using RFLP analysis. Cases and controls
showed a similar distribution of the SNP (P¼0.299). Genotype distribution showed neither an association with histopathological
characteristics of the tumours nor with prognosis. Age at disease onset was also not modified by the SNP. This first study of the
Mdm2 SNP309 in prostate cancer patients suggests no correlation between a certain allelic variant and an increased cancer risk.
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Genomic integrity and the ability of accurate repair of cellular
damage are crucial prerequisites for controlled proliferation and
differentiation. These processes are highly regulated and disruption
of components of this network favours malignant transformation.
The p53 protein is one of the most important coordinators of
cellular response to genotoxic stress (Levine 1997). The tumour
suppression functions of p53 are widespread and mediated by
various mechanisms. p53 is tightly regulated and the exact
mechanisms of p53 activation are still not fully understood
(Brooks and Gu, 2006). Several studies have shown that the major
mechanism of p53 control is its degradation by the ubiquitin-
proteasome pathway (Brooks and Gu, 2006). Human mouse
double-minute 2 protein (Mdm2) (gene locus on chromosome
12q14.3-q15) is a cellular E3 ligase able to ubiquinate and degrade
p53 (Haupt et al, 1997). As a key negative regulator of p53,
overexpression of Mdm2 is associated with accelerated tumour
progression and lack of response to therapy in various human
malignancies (Bond et al, 2004). Besides gene amplification, a
naturally occurring single-nucleotide polymorphism (SNP) in the
promoter of the Mdm2 gene (SNP309, T4G) was found that
increases mRNA and protein levels (Bond et al, 2004). Several
studies have analysed the impact of the Mdm2 SNP309 on cancer
risk in sporadic and hereditary malignancies and a recently
published meta-analysis revealed that there is only little effect on
the risk of common cancers from this SNP alone. Nevertheless, a
modification of the onset of tumour formation and the individual
prognosis might be influenced by this sequence variation
(Wilkening et al, 2007). Interestingly, Bond and co-workers found
an acceleration of tumour formation in a gender-specific and
hormone-dependent manner by this polymorphism (Bond et al,
2006).
Prostate cancer (PCa) poses one of the major health care
problems today. PCa is responsible for approximately 11% of all
male cancers in Europe, and about 9% of all cancer deaths in men
are caused by this malignancy within the European Union, the
course of this malignancy is unpredictable and therapy not
warranted in all patients (Heidenreich et al, 2008). A variety of
treatment options ranging from watchful waiting to radical surgery
underlines the necessity for the identification of reliable factors
permitting individual risk assessment.
Major progress in discovery of SNPs has lead to a rapid increase
of genetic association studies in various malignancies including
PCa. Despite promising results no specific PCa-related genes have
been established yet. However, the involvement of variants in
androgen pathway genes in PCa aetiology could recently be
confirmed reproducibly (Lindstro ¨m et al, 2006).
Alterations in the p53 pathway are already described in PCa
including Mdm2 protein overexpression in about 30–45% of the
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sanalysed tumours. This overexpression was associated with
advanced tumour stage, higher tumour volume and increased cell
proliferation (Osman et al, 1999; Leite et al, 2001; Khor et al, 2005).
Although these data indicate a potential role of Mdm2 over-
expression in PCa, there have been no studies published
investigating the distribution of the functional Mdm2 SNP309 in
PCa patients to date. Therefore, the aim of the presented study was
the analysis of the allele frequencies of the Mdm2 SNP309 in
patients with PCa compared to a healthy control group to assess a
possible influence of this promoter alteration on cancer risk,
histopathological tumour characteristics and prognosis.
MATERIALS AND METHODS
Samples
Overall, 145 patients with PCa were included in our study. All PCa
patients underwent a radical prostatectomy. Formalin-fixed and
paraffin-embedded tissue samples from these patients were
available from prior transurethral resection (TUR-P, n¼31) or
from the prostatectomy specimens (n¼114). For comparison 124
samples from a male control group of patients without any
malignancy acquired at the Department of Urology, University of
Regensburg was investigated.
All tumours were diagnosed according to the 2004 WHO
classification of prostate tumours (Epstein et al, 2004) and staged
according the TNM system (Sobin and Wittekind, 2002).
Characteristics of the study participants are shown in Table 1.
Detailed clinical information was available from 65 PCa patients.
Clinical follow-up (mean 71 months and range 6–144 months)
revealed that 20 tumours showed a recurrence within 3 years
(defined as detectable serum prostate specific antigen (PSA)
following radical prostatectomy (40.2ngml
 1), whereas 45
tumours did not recur within at least 5 years. Prior IRB approval
was obtained for the study.
Tissue microdissection and DNA isolation
DNA was extracted from normal prostate tissue or peripheral
blood using the High Pure PCR Template Preparation Kit (Roche
GmbH, Mannheim, Germany) according to the manufacturer’s
instructions.
Mdm2 SNP309 analysis
Single-nucleotide polymorphism analysis was carried out by
restriction fragment length polymorphism analysis (RFLP) of the
promoter region which contains an Msp A1I site (50-CMGCKG-30)
in presence of the G-allele (Sotomaa et al, 2005). The presence
of the G-allele resulted in a digest of the PCR product
(157/106þ51bp), PCR products containing the T-allele remained
unaffected.
Amplification of promoter region variants and RFLP
analysis
Single-nucleotide polymorphism region was amplified by PCR
using primers (5-FAM-sense: 50-CGCGGGAGTTCAGGGTAAAG-30;
antisense: 50-CTGAGTCAACCTGCCCACTG-30) obtained from
Metabion (Martinsried, Germany) in a total volume of 25ml contain-
ing approximately 100ng DNA, 0.2mM dNTP (Roche Diagnostics),
0.18mM primers and 0.0025Uml
 1 GoTaq (Promega, Mannheim,
Germany). The thermal cycling conditions were as follows: initial
denaturation for 3min at 951C, 35 cycles of denaturation at 951C
for 1min, annealing at 611C for 1min, elongation at 721C for 1min
and final primer extension at 721C for 10min.
PCR products were incubated overnight with 5U Msp A1I (New
England Biolabs, Frankfurt/Main, Germany) and 100mgml
 1 BSA
at 371C in a total volume of 30ml to ensure complete digestion.
Restriction fragments were separated by capillary electrophoresis
using an ABI PRISM 310 genetic analyser (Applied Biosystems,
Foster City, CA) and analysed with the GeneScan Analysis
Software. Representative examples of genotyping are shown in
Figure 1. Ten randomly selected cases were also sequenced to
verify the RFLP results. In all cases identical results were obtained
(data not shown).
Statistical analysis
To test if the genotype distribution followed Hardy–Weinberg
equilibrium, the public software at http://ihg.gsf.de/cgi-bin/hw/
hwa1.pl was used. w
2 statistics (two-sided Fisher’s exact test) were
used to evaluate case-control differences in the distribution of
genotypes and to analyse associations between genotypes and
clinical or histopathological characteristics. Po0.05 was
interpreted as statistically significant.
RESULTS
All analysed samples gave interpretable results. The genotype
distribution in our cohorts followed the Hardy–Weinberg
equilibrium in cases (P¼1.000) and controls (P¼0.578). Geno-
type distribution between cases and controls did not differ
significantly. Although there was a higher frequency of T/T
genotypes in prostate cancer patients this difference did not reach
statistical significance (P¼0.299, Table 2, Figure 2). There was also
Table 1 Characteristics of study participants
Cases Controls
Number: n¼145 n¼124
Age: Median: 65 Range: 46–74 Median: 69 Range: 40–88
Mean: 64.2 (±6.0) Mean: 68.5 (±9.9)
Stage: pT1-3a n¼105
pT3b-3c n¼28
No data available n¼12
Gleason score: Median: 7 Range: 3–10
Gleason sum: 3–4 n¼3
5–7 n¼103
8–10 n¼27
No data available n¼12
Recurrence: Recurrence within 3 years n¼20
No recurrence within 5 years n¼45
No data available n¼80
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sno association between overall disease risk and presence of the
polymorphic promoter variant (T/T vs T/GþG/G; P¼0.131,
Table 2). In addition, we also did not observe any significant
correlation of genotypes and disease recurrence or Gleason score
(Table 3). As the Mdm2 SNP309 was previously shown to be
related with disease onset at younger age also in sporadic tumours
(eg, bladder cancer (Sanchez-Carbayo et al, 2007)) we tested our
cases towards this hypothesis. Within our cohort there was no
significant association between genotypes and early disease onset
(p60 years vs 460 years, Table 3).
DISCUSSION
The Mdm2 SNP309 is a plausible cancer predisposing allele due to
the crucial role of Mdm2 in the cellular p53 pathway. The T to G
variant was shown to result in increased Mdm2 synthesis and was
found to be correlated with the risk of cancer or an early onset of
tumour formation at various organ sites (Hu et al, 2007). In this
study, we genotyped 145 cases of PCa and 124 male controls for
this polymorphism. In our cohort, we did not find any association
of the SNP309 with tumour risk, age at tumour onset, histopatho-
logical characteristics of the tumours or prognosis.
Overexpression of Mdm2 and its clinical consequences were
already described in PCa (Osman et al, 1999; Leite et al, 2001; Khor
et al, 2005) but the molecular basis of this upregulation is still
unclear. As our study revealed no significant changes in the allelic
distribution between PCa patients and men without any malig-
nancy, it is unlikely that the Mdm2 SNP309 plays an important role
for increased Mdm2 expression in prostate tumours. Moreover,
chromosomal deletions at 12q have not been described in PCa to
date, making a preferential loss of the Mdm2 T-allele resulting in a
Mdm2 overexpression during PCa development unlikely (Dumur
et al, 2003).
Mdm2 overexpression could be linked to gene amplification in
several malignancies (eg, malignant melanoma, non-small cell lung
cancer and lipomatous tumours (Dworakowska et al, 2004; Nilsson
et al, 2004; Muthusamy et al, 2006) but in PCa a specific Mdm2
gene amplification could not be demonstrated by Southern blot
analysis so far (Ittmann et al, 1994). Interestingly, frequent gains of
chromosome 12q including the regions 12q13-q14 that are in close
proximity to the Mdm2 gene locus have been reported in various
studies using comparative genomic hybridisation (Sattler et al,
1999; Zitzelsberger et al, 2001) but to date no gene copy number
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Figure 1 Representative examples for RFLP analyses. (A) T/G genotype resulting in an undigested 157bp product and a digested 51bp product. The
second fragment from the Msp A1I digest (106bp) is not visible due to 50-FAM-labelling of the PCR product. (B) T/T genotype showing only the 157bp
PCR product after Msp A1I digest. (C) G/G genotype displays only the 51bp after digest of the PCR product.
Table 2 Distribution of allelic variants between participants
Genotype Cases (%) Controls (%) Comparison
TT 61 (42.1) 41 (33.1)
GT 66 (45.5) 64 (51.6) P¼0.299
GG 18 (12.4) 19 (15.3)
TT 61 (42.1) 41 (33.1) P¼0.131 OR: 0.680 95% CI: 0.413–1.120
TG+GG 84 (57.9) 83 (66.9)
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Figure 2 Graphical illustration of the genotype distribution in cases and
controls.
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sanalysis specific for Mdm2 using highly sensitive, fluorescence-
based methods has been performed.
The G-variant of the Mdm2 promoter polymorphism increases
the affinity of transcription factors for example, Sp1. As long as
Mdm2 gene amplification is not analysed in detail in PCa,
overexpression of Sp1 might be speculated as an activator of
increased Mdm2 synthesis. Numerous studies have documented
that Sp1 activity and/or Sp1 expression levels are elevated in
various human cancers and are associated with prognosis (Safe
and Abdelrahim, 2005; Deniaud et al, 2006). In PCa elevated Sp1
levels have not been described so far but an increased expression
of Sp2 in PCa cells was found recently (Phan et al, 2004) indicating
a possible role of deregulation of Sp/KLF family member
expression in PCa.
Mdm2 is still discussed as a promising target for a therapeutical
approach (Vassilev, 2007). The identification of the first selective
and potent inhibitors of the p53-Mdm2 interaction emphasised the
usage of small-molecule inhibitors as viable alternative to
chemotherapy for selective p53 activation in tumours with wild-
type p53. In PCa p53 alterations are a rare event in primary
tumours and associated with more aggressive disease, metastasis
and transition from androgen-dependent to androgen-indepen-
dent growth (Dong, 2006). Therefore, a subset of prostate tumours
with Mdm2 overexpression might evolve as a suitable target for the
application of selective Mdm2 inhibitors in the future.
In conclusion, our case–control study suggests that the Mdm2
promoter polymorphism SNP309 has no influence on PCa risk or
prognosis, and relevant inherited alterations in PCa-related genes
remain to be uncovered.
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